In the financial year ending March 31, 2006, Sun Pharma reported total income of US$ 409 million, registering a 46.7 per cent growth over the previous year. The company had more than 5000 employees as on 31 March, 2006. Sun Pharma is the most profitable among all pharma companies in India, with a market capitalisation in excess of $4billion.

Global Footprint of Sun Pharmaceutical Industries Limited

Sun Pharma's manufacturing facilities are located in India, Bangladesh, Hungary and the USA. The company has 16 manufacturing sites, which primarily deal in either dosage forms or active pharmaceutical ingredients. The dosage forms include oral, injectable and delivery-based systems, while the APIs include peptides, steroids, hormones and anticancers.

Sun Pharmaceutical Industries Limited in the United States of America

Mode of Operation
Sun Pharma operates through two subsidiaries, one of which is a wholly-owned subsidiary. Currently, it operates through three manufacturing units in the USA.

Overview
Sun Pharma entered the US market in 1997, by acquiring a stake in Caraco Pharm Labs based in Detroit, Michigan. This marked the first international acquisition of the company. It invested...
Manufacturing facilities in Hungary from Valeant Pharmaceuticals. This acquisition made Sun Pharma one of the few companies in the world to have the approval to manufacture controlled substances right from the API stage.

Research and Development
Sun Pharma has been a consistent investor in research and development initiatives. It contributes nearly 10-12 per cent of its annual turnover in research; 4 per cent is invested in innovation. It has been one of the first pharmaceutical companies in India to set up a research laboratory. R&D was primarily undertaken to develop new products and APIs for India, the USA markets, and subsequently new molecules and delivery systems. The outcome of the thrust on R&D has resulted in an increased turnover from US$ 7.25 million in 1993 to over US$ 409 million in 2006.

Future Plans
With cash over US$ 500 million, Sun Pharma plans to undertake another acquisition in the USA in the generic domain. The company plans to focus on the generic market, as this segment is valued at over US$ 28 billion in the USA. The company also intends to enter the controlled substance space across various dosage forms.